[go: up one dir, main page]

WO2007012968A3 - Stable dosage form of an antidepressant - Google Patents

Stable dosage form of an antidepressant Download PDF

Info

Publication number
WO2007012968A3
WO2007012968A3 PCT/IB2006/002158 IB2006002158W WO2007012968A3 WO 2007012968 A3 WO2007012968 A3 WO 2007012968A3 IB 2006002158 W IB2006002158 W IB 2006002158W WO 2007012968 A3 WO2007012968 A3 WO 2007012968A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
antidepressant
stable dosage
relates
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2006/002158
Other languages
French (fr)
Other versions
WO2007012968A2 (en
Inventor
Viswaprasad Varanasi
Haranatha Babu Balanagu
Hidaytulla Shamshuddin Aga
Kishor Dattatray Deo
Sivakumaran Meenakshisunderam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurobindo Pharma Ltd
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Publication of WO2007012968A2 publication Critical patent/WO2007012968A2/en
Publication of WO2007012968A3 publication Critical patent/WO2007012968A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a stable solid dosage form comprising an anti-depressant compound. More particularly, the present invention relates to a stable solid dosage form comprising paroxetine HCl hemihydrate prepared by wet granulation process comprising lactose.
PCT/IB2006/002158 2005-07-29 2006-07-25 Stable dosage form of an antidepressant Ceased WO2007012968A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1039CH2005 2005-07-29
IN1039/CHE/2005 2005-07-29

Publications (2)

Publication Number Publication Date
WO2007012968A2 WO2007012968A2 (en) 2007-02-01
WO2007012968A3 true WO2007012968A3 (en) 2007-05-31

Family

ID=37683713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002158 Ceased WO2007012968A2 (en) 2005-07-29 2006-07-25 Stable dosage form of an antidepressant

Country Status (1)

Country Link
WO (1) WO2007012968A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109771381B (en) * 2017-11-13 2021-02-19 北京福元医药股份有限公司 Paroxetine medicinal preparation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102525966B (en) * 2010-12-13 2016-06-29 江苏万全特创医药生物技术有限公司 A kind of tablet containing paroxetine and preparation method thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158230A1 (en) * 2001-12-28 2003-08-21 Rakefet Cohen Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2004091617A1 (en) * 2003-04-17 2004-10-28 Glaxo Group Limited Combination of paroxetine and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)- (2s-phenyl-piperidin-3s-yl)-amine for treatment of depression and/or anxiety
WO2005034954A2 (en) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
US20060216345A1 (en) * 2005-03-24 2006-09-28 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition including paroxetine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158230A1 (en) * 2001-12-28 2003-08-21 Rakefet Cohen Stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2004091617A1 (en) * 2003-04-17 2004-10-28 Glaxo Group Limited Combination of paroxetine and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)- (2s-phenyl-piperidin-3s-yl)-amine for treatment of depression and/or anxiety
WO2005034954A2 (en) * 2003-10-08 2005-04-21 Ranbaxy Laboratories Limited Pharmaceutical compositions of paroxetine containing microcrystalline cellulose, prepared by wet granulation
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
US20060216345A1 (en) * 2005-03-24 2006-09-28 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition including paroxetine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109771381B (en) * 2017-11-13 2021-02-19 北京福元医药股份有限公司 Paroxetine medicinal preparation

Also Published As

Publication number Publication date
WO2007012968A2 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
WO2006065480A3 (en) Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
WO2007052289A3 (en) Novel dispersible tablet composition
WO2007093627A3 (en) Biocidal composition
EP2460797A3 (en) Process for preparation of ivabradine hydrochloride
AP2006003522A0 (en) Yd-crystalline form of ivabradine hydrochloride, a process for its preparation adn pharmaceutical compositions containing it.
WO2006074951A3 (en) Orally disintegrating composition of olanzapine or donepezil
WO2007127292A3 (en) Tigeycline crystalline forms and processes for preparation thereof
WO2010015657A3 (en) Alkoxypyrazoles and the process for their preparation
TW200720246A (en) Novel process for the preparation of acid chlorides
TW200621739A (en) Asymmetric synthesis of substituted dihydrobenzofurans
WO2007119114A3 (en) Improved synthesis and preparations of duloxetine salts
WO2006087143A8 (en) Novel processes for the preparation of a 2h-chromene
WO2008104880A3 (en) Stable solid dosage forms of an antidepressant
WO2006081515A3 (en) Duloxetine hydrochloride polymorphs
WO2005012227A3 (en) Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
WO2008035360A3 (en) Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
WO2010079506A3 (en) Pharmaceutical composition of aripiprazole
WO2007023342A3 (en) Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof
WO2006075139A3 (en) Novel process for the preparation of substituted indoles
WO2007012968A3 (en) Stable dosage form of an antidepressant
WO2009013594A3 (en) Process for the preparation of controlled-release solid formulations containing oxcarbazepine, and formulations obtainable by said process
WO2008007391A3 (en) An improved process for the preparation of valsartan
WO2007132344A3 (en) Controlled release compositions of an antidepressant agent
WO2007039076A3 (en) Niobium compound
WO2011022467A3 (en) Controlled-release formulations of anabaseine compounds and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06795217

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06795217

Country of ref document: EP

Kind code of ref document: A2